The FTC-Lilly Consent Decree

What it Means for PHARMA Vendors and Partners The 2002 settlement between ELi Lilly and the FTC regarding "unauthorized disclosure of sensitive personal information collected from consumers" has an impact beyond Lilly. It also affects its agents who collect personally identifiable information from consumers in "connection with the advertising, marketing, offering for sale, or sale of any pharmaceutical product." Such agents could include interactive agencies that build and maintain Web sites, direct marketing agencies, fulfillment centers, market researchers, etc. If you are a pharmaceutical service provider, read this commentary to learn what you need to do to be compliant with privacy and security standards demanded by your pharma clients. Read this article now. It's FREE... Download PDF file

PMN211-03
Issue: Vol. 2, No. 10: December 2003

Word Count: n/a

Find other articles in related Topic Areas:

• Direct-to-Consumer (DTC) Advertising & Marketing
• Regulatory Compliance